Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9545524 | 0.93 | TSHR (0.36) | TSHRALDH1A1 | |
| SCHEMBL28125990 | 0.82 | TSHR (0.30) | TSHRALDH1A1 | |
| SCHEMBL6567800 | 0.80 | TSHR (0.40) | TSHRFAAHTRPV1OPRM1THRB | |
| SCHEMBL28314155 | 0.78 | TSHR (0.44) | TSHRFAAHTRPV1THRBCNR1 | |
| SCHEMBL7698918 | 0.78 | DNM1 (0.40) | TSHRFAAHTRPV1OPRM1THRB | |
| SCHEMBL27682275 | 0.78 | TSHR (0.44) | TSHRFAAHTRPV1THRBCNR1 | |
| SCHEMBL10588790 | 0.78 | TSHR (0.44) | TSHRFAAHTRPV1THRBCNR1 | |
| SCHEMBL11091492 | 0.78 | TSHR (0.44) | TSHRFAAHTRPV1THRBCNR1 | |
| SCHEMBL1901792 | 0.78 | TSHR (0.44) | TSHRFAAHTRPV1THRBCNR1 | |
| SCHEMBL1758426 | 0.78 | TSHR (0.44) | TSHRFAAHTRPV1THRBCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1008346-B1 | NF-kB INHIBITORS CONTAINING BENZOQUINONE DERIVATIVES | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-02-15 | — | — | EP | disclosed |
| US-6943196-B1 | NF-κB inhibitor comprising phenylmethyl benzoquinone as the active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-09-13 | — | — | US | disclosed |
| US-20040030129-A1 | NF-kappaB inhibitor comprising phenylmethyl benzoquinone as an active ingredient | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-02-12 | — | — | US | disclosed |
| EP-1008346-A1 | NF-$g(k)B INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT PHENYLMETHYL BENZOQUINONE | SUNTORY LIMITED (JP) | 2000-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030129-A1 | NF-kappaB inhibitor comprising phenylmethyl benzoquinone as an active ingredient | NFKBIA, NFKB2, NFKB1 | TSHR 4822/4885PLA2G10 3436/4885FAAH 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.